Specimen Analysis Sample Clauses
The Specimen Analysis clause outlines the procedures and responsibilities related to the examination and testing of samples or materials provided under an agreement. Typically, this clause specifies who will conduct the analysis, the standards or methods to be used, and how the results will be communicated to the relevant parties. For example, it may require that a laboratory test a product batch for quality assurance before acceptance or shipment. The core function of this clause is to ensure that all parties have a clear understanding of how specimens will be evaluated, thereby reducing disputes over quality or compliance with contractual specifications.
Specimen Analysis. (SEE ADDENDUM #1)
Specimen Analysis. Test methods permitted by state law shall be utilized. For confirmation purposes of any test screened “non-negative,” Sodexo will retain only a laboratory certified by the Substance Abuse and Mental Health Services Administration (SAMHSA). The laboratory will be required to maintain strict compliance with federally approved chain-of-custody procedures, quality control, maintenance and scientific analytical methodologies.
Specimen Analysis. 1.5.1 CONTRACTOR shall perform full screening and confirmation of one (1) of the following panels for each CLIENT as requested by ADMINISTRATOR via Aversys. Panel #1, SSA Standard Drug Panel, including marijuana, cocaine, expanded opiates (morphine, heroin, hydrocodone, hydromorphone, oxycodone, and oxymorphone), phencyclidine, amphetamines, barbiturates, benzodiazepines, methadone, propoxyphene, and alcohol. Panel #2, Illicit Drug Panel Plus ethyl glucuronide (ETG) test, including cocaine, amphetamines, opiates, marijuana, benzodiazepines and ETG. Panel #3, Opioids, including benzodiazepines, buprenorphine, cocaine, rotation of fentanyl (34%), meperidine (33%) and tramadol (33%), opiates, oxycodone and marijuana. Panel #4, Synthetic THC.
1.5.2 CONTRACTOR shall, conduct a Breath Alcohol Content (BAC) test at no additional cost to COUNTY, on all CLIENTS that report to “In County” and Avertest LLC, dba Averhealth Owned and Operated “Out of County” client service centers and conduct an ETG test on all CLIENT samples submitted at an “Out of County / Avertest LLC dba Averhealth In-Network Facility.”
1.5.3 CONTRACTOR shall add, upon electronic request by ADMINISTRATOR, any one (1) or more of the following Specialty Drug Add-Ons to any of the test panels described above in Subparagraphs 1.5.
1.1 through 1.5.1.3 of Exhibit C: buprenorphine, carisoprodol, ETG, gabapentin, heroin (specific immunoassay test), ketamine, Lysergic Acid Diethylamide (LSD), meperidine, neurontin, tramadol, or zolpidem.
1.5.4 CONTRACTOR shall allow ADMINISTRATOR to order, within Aversys, customized test panels of varying substances, as needed, to meet CLIENTS’ needs as determined by ADMINISTRATOR. At the sole discretion of ADMINISTRATOR, such test panels may replace, for either groups or individuals, any test panel described above in Subparagraphs 1.5.1.1 through 1.5.1.3 of Exhibit C. Pricing for customized panels shall be at CONTRACTOR’s catalog price.
1.5.5 CONTRACTOR acknowledges that ADMINISTRATOR has the option to rotate panels described in Subparagraph 1.5.1 of Exhibit C.
1.5.6 CONTRACTOR shall ensure specimen integrity by visually inspecting all samples to evaluate color and clarity, and evaluating the specimen potential of hydrogen (pH) to ascertain that it falls within an acceptable range. Each drug screen shall include creatinine and nitrite level tests to check for dilution and commercial adulterants.
1.5.7 CONTRACTOR shall test specimens with creatinine values less than 20.0 mg...
Specimen Analysis. Test methods permitted by state law shall be utilized. For